BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 19502267)

  • 21. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis.
    Korendowych E; Owen P; Ravindran J; Carmichael C; McHugh N
    Rheumatology (Oxford); 2005 Aug; 44(8):1056-60. PubMed ID: 15901902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.
    Bos WH; Ursum J; de Vries N; Bartelds GM; Wolbink GJ; Nurmohamed MT; van der Horst-Bruinsma IE; van de Stadt RJ; Crusius JB; Tak PP; Dijkmans BA; van Schaardenburg D
    Ann Rheum Dis; 2008 Sep; 67(9):1347-50. PubMed ID: 18388157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
    Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
    Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations.
    Korkmaz C; Us T; Kaşifoğlu T; Akgün Y
    Clin Biochem; 2006 Oct; 39(10):961-5. PubMed ID: 16979149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis.
    Cha S; Choi CB; Han TU; Kang CP; Kang C; Bae SC
    Arthritis Rheum; 2007 May; 56(5):1454-63. PubMed ID: 17469103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
    Zhao J; Zhao Y; He J; Jia R; Li Z
    J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis].
    Dijkmans BA; van Schaardenburg D; van der Horst-Bruinsma IE; Reesink HW; Vandenbroucke JP; Boers M
    Ned Tijdschr Geneeskd; 2005 Mar; 149(13):688-93. PubMed ID: 15819133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis.
    Candia L; Marquez J; Gonzalez C; Santos AM; Londoño J; Valle R; Zabaleta J; Yaqub Z; Espinoza LR
    J Clin Rheumatol; 2006 Oct; 12(5):226-9. PubMed ID: 17023808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis.
    Ferucci ED; Majka DS; Parrish LA; Moroldo MB; Ryan M; Passo M; Thompson SD; Deane KD; Rewers M; Arend WP; Glass DN; Norris JM; Holers VM
    Arthritis Rheum; 2005 Jan; 52(1):239-46. PubMed ID: 15641089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of anti cyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis.
    Shankar S; Grover R; Handa R
    Indian J Med Res; 2006 Dec; 124(6):689-96. PubMed ID: 17287557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis.
    Kapitány A; Szabó Z; Lakos G; Aleksza M; Végvári A; Soós L; Karányi Z; Sipka S; Szegedi G; Szekanecz Z
    Isr Med Assoc J; 2008 Jan; 10(1):32-6. PubMed ID: 18300568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies.
    Kogure T; Tatsumi T; Fujinaga H; Niizawa A; Terasawa K
    Mediators Inflamm; 2007; 2007():12367. PubMed ID: 17497027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis.
    van Oosterhout M; Bajema I; Levarht EW; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2008 Jan; 58(1):53-60. PubMed ID: 18163491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.
    Payet J; Goulvestre C; Bialé L; Avouac J; Wipff J; Job-Deslandre C; Batteux F; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2014 Dec; 41(12):2395-402. PubMed ID: 25274898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides.
    Pedersen M; Jacobsen S; Klarlund M; Pedersen BV; Wiik A; Wohlfahrt J; Frisch M
    Arthritis Res Ther; 2006; 8(4):R133. PubMed ID: 16872514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis.
    Mutlu N; Bicakcigil M; Tasan DA; Kaya A; Yavuz S; Ozden AI
    J Rheumatol; 2009 Mar; 36(3):491-500. PubMed ID: 19228660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis].
    Galati S; Beauvillain C; Renier G; Jeannin P; Masson C; Chevailler A
    Ann Biol Clin (Paris); 2008; 66(2):157-64. PubMed ID: 18390426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status.
    Ball EM; Tan AL; Fukuba E; McGonagle D; Grey A; Steiner G; Bell AL; Rooney MR
    Rheumatology (Oxford); 2014 Oct; 53(10):1835-43. PubMed ID: 24850876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis.
    Christensen AF; Lindegaard H; Hørslev-Petersen K; Hetland ML; Ejbjerg B; Stengaard-Pedersen K; Jacobsen S; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Tarp U; Pødenphant J; Østergaard M; Junker P
    J Rheumatol; 2011 Aug; 38(8):1563-8. PubMed ID: 21572145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.